Our team’s focus is on relationships with early-stage innovative companies across the world in our thematic areas of interest.
 

From our experience, successful engagements often start with companies that meet the following criteria:

For business-sponsored collaborations and investments:

 

  • Well-rounded and experienced founding team
  • Seed level and above, to Series B
  • Clearly defined and validated solution
  • Regulatory pathway completed or in progress
  • In-line with the Philips focus areas
  • While geographically agnostic; proximity to relevant Philips sites does support collaboration

For the Philips Health Technology Venture Fund:

  • Series A/B stage
  • Initial investment of $2 million – $5 million EUR/USD, reserves at twice initial investment
  • We syndicate all deals
  • Company maturity at early commercial stage
  • Investment goal is to confirm product validation / value proposition and drive scale

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.

You are entering a Philips Healthcare Australia website
Please select the checkbox

The information on this site is not intended for consumers. The information is directed exclusively to health professionals, health practitioners, persons who are purchasing officers in hospitals, and persons who are engaged in the business of wholesaling therapeutic goods (as per s42AA of the Therapeutic Goods Act 1989 (Cth), and s6 of the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021).

By clicking “Continue” you are indicating that you are one of the intended audiences. Click cancel to be redirected to the Philips website.